ArticleCureus2025
Therapeutic Endoscopic Interventions in Choledocholithiasis: Efficacy of Endoscopic Retrograde Cholangiopancreatography.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCholedocholithiasis, a condition characterized by stones in the common bile duct (CBD), frequently results in obstructive jaundice and associated complications. Endoscopic retrograde cholangiopancreatography (ERCP) has emerged as the gold standard for treating this condition, offering a minimally invasive therapeutic approach. However, while ERCP is widely used, its efficacy in managing diverse clinical presentations and potential complications necessitates further investigation. Additionally, data on ERCP's effectiveness in various clinical scenarios, particularly concerning stone size and location, remain inconsistent, highlighting the need for more comprehensive research in this area.
objectiveThis study aims to evaluate the effectiveness of ERCP as a therapeutic intervention for choledocholithiasis, focusing on procedural outcomes, stone clearance rates, and associated complications.
methodsA retrospective study was conducted on 50 patients diagnosed with choledocholithiasis who underwent ERCP at a tertiary care hospital between January 2022 and December 2023. Data on patient demographics, clinical presentation, imaging, laboratory findings, and procedural outcomes were collected. ERCP procedures, including endoscopic sphincterotomy (ES) with balloon extraction and stenting, were performed by experienced endoscopists. Statistical analysis was done using SPSS version 25.
resultsThe majority of patients were aged 31-70 years, with abdominal pain (96%) being the most common symptom. ERCP successfully cleared the CBD in 76% of cases in a single session, with repeat ERCP required for 18% of patients. Complications occurred in 20% of cases, with pancreatitis (10%) being the most common. Smaller stones (≤10 mm) had higher success rates for single-session clearance, while larger stones (>15 mm) often required repeat procedures or surgery. Distal CBD stones were cleared more effectively compared to those in proximal locations.
conclusionERCP remains an effective and safe treatment for choledocholithiasis, particularly for smaller and distal CBD stones. The procedure's safety and efficacy support its continued use as the gold standard for managing choledocholithiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.